|Day Low/High||79.88 / 81.75|
|52 Wk Low/High||75.62 / 107.24|
- Nineteen abstracts underscore AbbVie's continued pursuit of research on behalf of patients living with chronic dermatologic conditions
AbbVie to provide multi-million-dollar financing to Voyager to develop and commercialize potential Parkinson's treatment.
- Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein
- Upadacitinib, an investigational once-daily oral JAK1-selective inhibitor, is being studied for the treatment of adult patients with moderate to severe rheumatoid arthritis[1-8]
NORTH CHICAGO, Ill. and MENLO PARK, Calif.
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc.
Of the 57 index constituents, four Aristocrats have yields above 4.0%.
Jim Cramer says that if expectations are too high, even a great quarter cannot save you from the wave of selling.
Jim Cramer takes a look at Carvana, Bank OZK, Idexx Labs, Patterson-UTI Energy, 3D Systems, AbbVie and more.
- Milestone marks the 10th FDA approval for IMBRUVICA in six different disease areas since 2013
Stocks rose by Friday's close, getting a boost from a number of strong corporate earnings reports even as investors continue to worry about a lack of progress in U.S.-China trade talks.
The pharmaceutical company reports fourth-quarter results below analysts' consensus forecasts.
China's central bank announced a bill swap mechanism late Thursday aimed at slowing down the nation's economic slowdown.
- Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent
-- The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents
One of pharma's biggest CEO's talks M&A action on the exchange.
Jim Cramer talks about the Fed, and outlines your game plan.
Jim Cramer weighs in on Qualcomm, Momo, Ciena, AbbVie, LM Ericsson and more.
Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.
And it is happening not a moment too soon.
- Initiation of clinical studies with TTX-030 is targeted in Q1 2019
Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.
ABBV offers an ideal mix of growth, value and income.
- Regulatory applications supported by robust SELECT Phase 3 program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis[1-5]
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.